Skip to content

Sample Page

Author: BioNxt Solutions Inc.

Posted Date:

July 6, 2026

BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway

BioNxt Solutions Inc.

July 6, 2026
BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF

BioNxt Solutions Inc.

June 15, 2026
BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development

BioNxt Solutions Inc.

May 19, 2026
BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)

BioNxt Solutions Inc.

April 14, 2026
BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries

BioNxt Solutions Inc.

April 7, 2026
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy

BioNxt Solutions Inc.

March 30, 2026
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe

BioNxt Solutions Inc.

March 17, 2026
BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis

BioNxt Solutions Inc.

February 17, 2026
BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion

BioNxt Solutions Inc.

January 28, 2026